IGM Biosciences pivoted to autoimmune disease, reducing R&D expenses. The company reported a net loss of $61.4 million. CEO ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM ...

Institutional investors and hedge funds own 42.79% of the company’s stock. IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the ...

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.04 per share a year ago.

Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by ...

Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on IGM Biosciences (IGMS – Research Report) today and set a price target ...

MOUNTAIN VIEW, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today ...

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to loss of $1.04 per share a year ago. These ...